Mark A. Smith
Directeur Technique/Scientifique/R&D chez BRIGHT MINDS BIOSCIENCES INC.
Fortune : - $ au 30/04/2024
Profil
Mark A.
Smith is currently the Chief Medical Officer at Bright Minds Biosciences, Inc. He previously worked as the Executive Director-Clinical Development at AstraZeneca PLC from 2000 to 2012, as the Senior Director-Experimental Medicine at Shire Plc from 2012 to 2013, and as the Chief Medical Officer at VistaGen Therapeutics, Inc. from 2016 to 2022.
Dr. Smith received his undergraduate and graduate degrees from Yale University and his doctorate from the University of California San Diego.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/12/2022 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Mark A. Smith
| Sociétés | Poste | Début |
|---|---|---|
| BRIGHT MINDS BIOSCIENCES INC. | Directeur Technique/Scientifique/R&D | 01/12/2022 |
Anciens postes connus de Mark A. Smith
| Sociétés | Poste | Fin |
|---|---|---|
| VISTAGEN THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/12/2022 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/10/2013 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/09/2012 |
Formation de Mark A. Smith
| Yale University | Graduate Degree |
| University of California San Diego | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| VISTAGEN THERAPEUTICS, INC. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| BRIGHT MINDS BIOSCIENCES INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
